title: Fluoroquinolone-related neuropsychiatric and mitochondrial toxicity: a collaborative investigation by scientists and members of a social network.
abstract: BACKGROUND
  The 3 fluoroquinolone (FQ) antibiotics - ciprofoxacin, levofoxacin, and moxifoxacin - are commonly administered to oncology patients. Although these oral antibiotics are approved by the US Food and Drug Administration (FDA) for treatment of urinary tract infections, acute bacterial sinusitis, or bacterial infection in patients with chronic obstructive pulmonary disease, they are commonly prescribed off-label to neutropenic cancer patients for the prevention and treatment of infections associated with febrile neutropenia. New serious FQ-associated safety concerns have been identified through novel collaborations between FQ-treated persons who have developed long-term neuropsychiatric (NP) toxicity, pharmacovigilance experts, and basic scientists.
  
  
  OBJECTIVE
  To conduct basic science and clinical investigations of a newly identified adverse drug reaction, termed FQ-associated disability.
  
  
  METHODS
  5 groups of C57BL/6 mice receiving the antibiotic ciprofoxacin in 10-mg increments (10 mg/kg-50 mg/kg) and 1 group of control mice were evaluated. The Southern Network on Adverse Reactions (SONAR) and a social network of FQ-treated persons with long-term NP toxicity (the Floxed Network) conducted a web-based survey. The clinical toxicity manifestations reported by 94 respondents to the web-based survey of persons who had received 1 or more doses of an FQ prescribed for any indication (generally at FDA-approved dosages) and who subsequently experienced possible adverse drug reactions were compared with adverse event information included on the product label for levofoxacin and with FQ-associated adverse events reported to the FDA's MedWatch program.
  
  
  RESULTS
  Mice treated with ciprofoxacin had lower grip strengths, reduced balance, and depressive behavior compared with the controls. For the survey, 93 of 94 respondents reported FQ-associated events including anxiety, depression, insomnia, panic attacks, clouded thinking, depersonalization, suicidal thoughts, psychosis, nightmares, and impaired memory beginning within days of FQ initiation or days to months of FQ discontinuation. The FDA Adverse Event Reporting System (FAERS) included 210,705 adverse events and 2,991 fatalities for FQs. Levofoxacin and ciprofoxacin toxicities were neurologic (30% and 26%, respectively), tendon damage (8% and 6%), and psychiatric (10% and 2%). In 2013, an FDA safety review reported that FQs affect mammalian topoisomerase II, especially in mitochondria. In 2013 and 2014, SONAR fled citizen petitions requesting black box revisions identifying neuropsychiatric toxicities and mitochrondrial toxicity as serious levofoxacin-associated adverse drug reactions. In 2015, FDA advisors recommended that FQ product labels be revised to include information about this newly identified disability syndrome termed "FQ-associated disability" (FQAD).
  
  
  CONCLUSIONS
  Basic science studies evaluated NP toxicity for only 1 FQ, ciprofoxacin.
  
  
  CONCLUSIONS
  Pharmacovigilance investigators, a social network, and basic scientists can collaborate on pharmacovigilance investigations. Revised product labels describing a new serious adverse drug reaction, levofoxacin-associated long-term disability, as recommended by an FDA advisory committee, are advised.
authors.affiliation: Applied Physiology Division, Department of Exercise Science, University of South Carolina, Columbia, South Carolina, USA.
authors.forename: Kamaljeet
authors.initials: K
authors.lastname: Kaur
authors.affiliation: Applied Physiology Division, Department of Exercise Science, University of South Carolina, Columbia, South Carolina, USA.|Center for Colon Cancer Research, University of South Carolina, Columbia, South Carolina, USA.
authors.forename: Raja
authors.initials: R
authors.lastname: Fayad
authors.affiliation: Applied Physiology Division, Department of Exercise Science, University of South Carolina, Columbia, South Carolina, USA.
authors.forename: Arpit
authors.initials: A
authors.lastname: Saxena
authors.affiliation: Department of Pharmacology, Physiology and Neuroscience, USC Shoool of Medicine, University of South Carolina, Columbia, South Carolina, USA.
authors.forename: Norma
authors.initials: N
authors.lastname: Frizzell
authors.affiliation: Department of Environment Health Sciences, University of South Carolina, Columbia, South Carolina, USA.
authors.forename: Anindya
authors.initials: A
authors.lastname: Chanda
authors.affiliation: Department of Environment Health Sciences, University of South Carolina, Columbia, South Carolina, USA.
authors.forename: Suvarthi
authors.initials: S
authors.lastname: Das
authors.affiliation: Department of Environment Health Sciences, University of South Carolina, Columbia, South Carolina, USA.
authors.forename: Saurabh
authors.initials: S
authors.lastname: Chatterjee
authors.affiliation: Applied Physiology Division, Department of Exercise Science, University of South Carolina, Columbia, South Carolina, USA.
authors.forename: Shweta
authors.initials: S
authors.lastname: Hegde
authors.affiliation: Department of Research, Father Muller Medical College, Mangalore, Karnataka, India.
authors.forename: Manjeshwar Shrinath
authors.initials: MS
authors.lastname: Baliga
authors.affiliation: Fortis-Totipotent RX Centre for Cellular Medicine, Delhi, India.
authors.forename: Venkatesh
authors.initials: V
authors.lastname: Ponemone
authors.affiliation: Applied Physiology Division, Department of Exercise Science, University of South Carolina, Columbia, South Carolina, USA.
authors.forename: Matthew
authors.initials: M
authors.lastname: Rorro
authors.affiliation: Applied Physiology Division, Department of Exercise Science, University of South Carolina, Columbia, South Carolina, USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Greene
authors.affiliation: Applied Physiology Division, Department of Exercise Science, University of South Carolina, Columbia, South Carolina, USA.
authors.forename: Yasmine
authors.initials: Y
authors.lastname: Elraheb
authors.affiliation: Department of Anthropology, University of Kansas, Lawrence, Kansas, USA.
authors.forename: Alan J
authors.initials: AJ
authors.lastname: Redd
authors.affiliation: Southern Network on Adverse Reactions (SONAR), South Carolina Center of Economic Excellence for Medication Safety, College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA.
authors.forename: John
authors.initials: J
authors.lastname: Bian
authors.affiliation: Southern Network on Adverse Reactions (SONAR), South Carolina Center of Economic Excellence for Medication Safety, College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA.
authors.forename: John
authors.initials: J
authors.lastname: Restaino
authors.affiliation: Southern Network on Adverse Reactions (SONAR), South Carolina Center of Economic Excellence for Medication Safety, College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA.|Dorn Research Institute, Columbia, South Carolina, USA.
authors.forename: LeAnn B
authors.initials: LB
authors.lastname: Norris
authors.affiliation: Southern Network on Adverse Reactions (SONAR), South Carolina Center of Economic Excellence for Medication Safety, College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA.|Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.
authors.forename: Zaina P
authors.initials: ZP
authors.lastname: Qureshi
authors.affiliation: Southern Network on Adverse Reactions (SONAR), South Carolina Center of Economic Excellence for Medication Safety, College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA.|Dorn Research Institute, Columbia, South Carolina, USA.
authors.forename: Bryan L
authors.initials: BL
authors.lastname: Love
authors.affiliation: Southern Network on Adverse Reactions (SONAR), South Carolina Center of Economic Excellence for Medication Safety, College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA.
authors.forename: Brandon
authors.initials: B
authors.lastname: Brookstaver
authors.affiliation: Southern Network on Adverse Reactions (SONAR), South Carolina Center of Economic Excellence for Medication Safety, College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA.|Dorn Research Institute, Columbia, South Carolina, USA.|Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.
authors.forename: Peter
authors.initials: P
authors.lastname: Georgantopoulos
authors.affiliation: Tulane University School of Medicine, New Orleans, Louisiana, USA.
authors.forename: Oliver
authors.initials: O
authors.lastname: Sartor
authors.affiliation: College of Pharmacy, University of New Mexico, Albuquerque, New Mexico, USA.
authors.forename: Dennis W
authors.initials: DW
authors.lastname: Raisch
authors.affiliation: Southern Network on Adverse Reactions (SONAR), South Carolina Center of Economic Excellence for Medication Safety, College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA.|Dorn Research Institute, Columbia, South Carolina, USA.
authors.forename: Gowtham
authors.initials: G
authors.lastname: Rao
authors.affiliation: Southern Network on Adverse Reactions (SONAR), South Carolina Center of Economic Excellence for Medication Safety, College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA.
authors.forename: Kevin
authors.initials: K
authors.lastname: Lu
authors.affiliation: Southern Network on Adverse Reactions (SONAR), South Carolina Center of Economic Excellence for Medication Safety, College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA.
authors.forename: Paul
authors.initials: P
authors.lastname: Ray
authors.affiliation: Oncology Analytics Inc, Plantation, Florida, USA.
authors.forename: William
authors.initials: W
authors.lastname: Hrusheshky
authors.affiliation: Southern Network on Adverse Reactions (SONAR), South Carolina Center of Economic Excellence for Medication Safety, College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA.
authors.forename: Richard
authors.initials: R
authors.lastname: Schulz
authors.affiliation: Department of Pathology, University of Arizona College of Medicine, The Arizona Cancer Institute and BIO5 Institute, Tucson, Arizona, USA.
authors.forename: Richard
authors.initials: R
authors.lastname: Ablin
authors.affiliation: Southern Network on Adverse Reactions (SONAR), South Carolina Center of Economic Excellence for Medication Safety, College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA.
authors.forename: Virginia
authors.initials: V
authors.lastname: Noxon
authors.affiliation: Southern Network on Adverse Reactions (SONAR), South Carolina Center of Economic Excellence for Medication Safety, College of Pharmacy, University of South Carolina, Columbia, South Carolina, USA. bennettc@sccp.sc.edu.|Dorn Research Institute, Columbia, South Carolina, USA.
authors.forename: Charles L
authors.initials: CL
authors.lastname: Bennett
keywords: Southern Network on Adverse Reactions (SONAR); adverse drug reactions; fluoroquinolones; neuropsychiatric toxicity